

# Decentralized Trial Activities Reported in Publicly Available Clinical Trial Protocols


**Amos J. de Jong,**<sup>1</sup> Renske J. Grupstra,<sup>1</sup> Yared Santa-Ana-Tellez,<sup>1</sup> Mira G.P. Zuidgeest, <sup>2</sup> Anthonius de Boer, <sup>1</sup> Helga Gardarsdottir, <sup>1</sup> On behalf of the Trials@Home Consortium<sup>3</sup>

Utrecht Institute for Pharmaceutical Sciences, Utrecht University
Julius Center for Health Sciences and Primary Care, University Medical
Center Utrecht
trialsathome.com

# INTRODUCTION

Decentralized trial activities, such as recruitment via social media, data collection through wearable devices, telemedicine and home health visits, and shipment of IMP to trial participants' homes, have the promise to improve clinical trial conduct. For example, these decentralized trial activities could enable more participant-centered clinical trials by lowering the number of required on-site visits.


### RESULTS



The Covid-19 pandemic has furthermore increased the interest in and uptake of decentralized trial activities to ensure participant safety and trial integrity. However, there is limited insight in the extent to which decentralized trial activities are implemented in clinical trials.

# GOAL

To investigate the occurence of decentralized and on-site conduct of trial activities as reported in publicly available clinical trial protocols with a study start in 2019 or 2020.



For all trial activities, on-site conduct was more frequently reported than decentralized conduct

### Sub-group analyses

15<sub>「</sub>



of protocols

%


25


# METHOD

Publicly available protocols from phase 2, 3, 4 interventional clinical drug trials with a start date in 2019 and 2020 were downloaded from ClinicalTrials.gov.


Decentralized and on-site conduct of the following operational trial activities was manually ascertained: participant outreach, pre-screening, screening, obtaining informed consent, asynchronous communication, participant training, IMP supply, IMP adherence monitoring, CT monitoring, staff training, and data collection.

**RESEARCH HIGHLIGHTS** 







Public sponsors (yellow) reported more decentralized consenting than private sponsors (blue)



Phase 2 (yellow) and 3 (blue) reported more decentralized data collection than phase 4 protocols (green)



In North America (yellow) more decentralized outreach was reported than in Europe (blue) and other regions (green)



Increasing trends were seen over time: decentralized consenting is shown as an example

### CONCLUSIONS

68.9% of the protocols reported decentralized data collection 1.6% of the protocols reported exclusively decentralized data collection Differences between trial regions, phases, sponsors, and over time exist

Decentralized trial activities have been included in publicly available trial protocols, although on-site activities were reported more often for all investigated trial activities. Of the decentralized trial acitvities, decentralized data collection is used most commonly in clinical trials. Decentralized trial elements are more frequently reported in protocols from 2020, possibly due to COVID-19. Sharing best practices can now progress future use of decentralized trial activities to benefit trial participants.

This research was conducted as part of the Trials@Home consortium. This work has received support from the EU/EFPIA Innovative Medicines Initiative Joint Undertaking Trials@Home (grant No 831458). This poster reflects the views of the Trials@Home consortium and neither IMI nor the European Union and EFPIA are liable for any use that may be made of the information contained herein.





https://trialsathome.com/ https://www.imi.europa.eu/ Mail.europa.eu/ Mail.europa.e